Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Ear-puffing device for migraine treatment wins FDA breakthrough designation

April 28, 2022 By Jim Hammerand

A woman with a small, handheld device in her lap with tubes that look like earphones plugged into hear ears.

Nocira’s AVPI migraine treatment device [Photo courtesy of Nocira]

A handheld device that treats migraine attacks with puffs of air in a patient’s ears has been designated a breakthrough device by the FDA.

Tempe, Arizona–based Nocira said it is the first company to announce breakthrough device designation for treating migraine attacks in both chronic and non-chronic migraine patients ages 18 and up.

The device uses “gentle, controlled puffs of air in the ears” to subtly change pressure in the external ear canal, a drug-free technology that Nocira calls Automated Variable Pulse Insufflation (AVPI).

“This therapeutically stimulates a unique combination of pressure-responsive nerve pathways from the ear into areas of the brain associated with headache pain and other migraine symptoms,” the company said yesterday in a news release.

A smartphone app controls the noninvasive, handheld air pressure device and responds to the patient’s input of migraine symptoms to customize treatment.

Nocira said it plans to submit for FDA premarket review and authorization within the year.

Breakthrough device designation “will clearly help us expedite the next remaining steps ahead for regulatory and commercialization pathways for making this disruptive new Nocira device available to tens of millions of migraine sufferers in the future,” Nocira CEO Jim Peacock said in the news release.

Device developers that win breakthrough designation can opt to keep that status secret, but two other prior designations have been announced specifically for migraines, Nocira said. Both were limited to preventative use for chronic migraine patients, defined as those who experience 15 headache days per month.

“In granting this breakthrough device designation, the FDA was required to determine that the clinical data supporting the Nocira device provides a reasonable expectation for a more effective treatment versus other available therapies for acutely treating migraine attacks,” Nocira VP of Regulatory, Quality, and Clinical Affairs Melissa Walker said in the news release. 

In a peer-reviewed, published study with 59 patients randomly assigned treatment with the device or with a sham placebo, Nocira said 90% of patients had significant headache pain relief (defined as a 50% reduction in pain) within 20 minutes of using the device, a figure that increased to 93% over two hours.

Of the patients who used the device, 60% reported complete relief from headache pain within 20 minutes and 67% within two hours.

Of the patients in the sham group, 7% reported complete freedom from headache pain within 20 minutes and then 2 hours, while 31 percent reported significant relief in the same timeframe.

Nocira said the patient relief rates were 20% to 47% better than other published trials for currently available drugs and devices.

“Complete freedom from other primary migraine symptoms (i.e., nausea, light sensitivity and sound sensitivity) was also rapidly achieved for most migraine attacks treated with the Nocira device,” the company said. “High relief rates were also observed in both chronic and episodic migraine patients, and for migraines that were either with or without ‘aura’ (certain visual disturbances).”

More than 90% of study participants said the Nocira migraine treatment was a comfortable experience, and there were no significant safety issues reported.

Nocira said it is continuing more advanced clinical development and evaluation efforts.

Nocira was founded in 2014 by Chief Scientific Officer David George, David Sullivan, George Buckler and Board Chair Tim Crown, who is Nocira’s lead investor and a co-founder of Insight Enterprises (Nasdaq:NSIT).

You may also like:

  • migraine
    This medtech is giving hope to migraine sufferers

  • Theranica lands VA contract for migraine device

  • FDA clears Theranica device for adolescent migraines

Related Articles Read More >

A portrait of Keri Mattox, Zimmer Biomet's chief communications and administration officer
Zimmer Biomet adds ESG and CEO visibility to executive’s duties
A portrait of Geoff Martha, CEO of Medtronic
‘Catastrophic explosion’ and resin shortage led Medtronic’s supply chain problems
A portrait of Dr. Kevin Chung, chief medical officer at SeaStar Medical
Device developer SeaStar Medical hires chief medical officer
MedAcuity
MedAcuity hires SVP of business development

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech